FDA New Drug and Biologic Approvals, 2018 Midyear Review
In This Issue
The FDA New Drug and Biologic Approvals, 2018 Midyear Review describes new molecular entities, new biologics, and select new indications by condition for those drugs and biologics approved during the first half of this year. Each summary contains information on the indication, mechanism, dosage, and clinical trials that served as the basis for the FDA approval. For more information, each drug or biologic is linked to its corresponding Medscape drug monograph.